
United States
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 11-K

**FOR ANNUAL REPORTS OF EMPLOYEE STOCK
PURCHASE, SAVINGS AND SIMILAR PLANS
PURSUANT TO SECTION 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934**

(Mark One)

ANNUAL REPORT PURSUANT TO SECTION 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

FOR THE FISCAL YEAR ENDED DECEMBER 31, 2020

OR

TRANSITION REPORT PURSUANT TO SECTION 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

FOR THE TRANSITION PERIOD FROM TO

COMMISSION FILE NUMBER: 001-35092

A. Full title of the plan and the address of the plan, if different from that of the issuer named below:

EXACT SCIENCES CORPORATION 401(K) PLAN

B. Name of issuer of the securities held pursuant to the plan and the address of its principal executive office:

EXACT SCIENCES CORPORATION

**5505 Endeavor Lane,
MADISON, WI 53719**

EXACT SCIENCES CORPORATION 401(K) PLAN
TABLE OF CONTENTS

	<u>Page No.</u>
Report of Independent Registered Public Accounting Firm	3
Financial Statements:	
Statements of net assets available for benefits as of December 31, 2020 and 2019	5
Statement of changes in net assets available for benefits for year ended December 31, 2020	6
Notes to financial statements	7
Supplemental Schedules:	
Schedule H, Line 4(a) — Schedule of delinquent participant contributions for the year ended December 31, 2020	15
Schedule H, Line 4(i) — Schedule of assets (held at end of year) December 31, 2020	16
Signature	18
Exhibit Index	19

Report of Independent Registered Public Accounting Firm

To the Administrator and Plan Participants of Exact Sciences Corporation 401(K) Plan

Opinion on the Financial Statements

We have audited the accompanying statement of net assets available for benefits of Exact Sciences Corporation 401(K) Plan (the “Plan”) as of December 31, 2020 and the related statement of changes in net assets available for benefits for the year then ended, including the related notes (collectively referred to as the “financial statements”). In our opinion, the financial statements present fairly, in all material respects, the net assets available for benefits of the Plan as of December 31, 2020, and the changes in net assets available for benefits for the year then ended in conformity with accounting principles generally accepted in the United States of America.

Basis for Opinion

These financial statements are the responsibility of the Plan’s management. Our responsibility is to express an opinion on the Plan’s financial statements based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (PCAOB) and are required to be independent with respect to the Plan in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.

We conducted our audit of these financial statements in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud.

Our audit included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audit also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audit provides a reasonable basis for our opinion.

Supplemental Information

The supplemental schedules, Schedule H, Part 1V, Line 4a – Schedule of Delinquent Participant Contributions for the year ended December 31, 2020 and Schedule H, Part IV, Line 4i - Schedule of Assets Held (At End of Year) as of December 31, 2020 have been subjected to audit procedures performed in conjunction with the audit of the Plan’s financial statements. The supplemental schedules are the responsibility of the Plan’s management. Our audit procedures included determining whether the supplemental schedules reconcile to the financial statements or the underlying accounting and other records, as applicable, and performing procedures to test the completeness and accuracy of the information presented in the supplemental schedules. In forming our opinion on the supplemental schedules, we evaluated whether the supplemental schedules, including their form and content, are presented in conformity with the Department of Labor’s Rules and Regulations for Reporting and Disclosure under the Employee Retirement Income Security Act of 1974. In our opinion, the supplemental schedules are fairly stated, in all material respects, in relation to the financial statements as a whole.

/s/PricewaterhouseCoopers LLP
Chicago, Illinois
June 29, 2021

We have served as the Plan’s auditor since 2021.

Report of Independent Registered Public Accounting Firm

Plan Administrator and Participants
Exact Sciences Corporation 401(k) Plan
Madison, Wisconsin

Opinion on the Financial Statements

We have audited the accompanying statement of net assets available for benefits of the Exact Sciences Corporation 401(k) Plan (the “Plan”) as of December 31, 2019, and the related notes (collectively, the “financial statements”). In our opinion, the financial statements present fairly, in all material respects, the net assets available for benefits of the Plan as of December 31, 2019, in conformity with accounting principles generally accepted in the United States of America.

Basis for Opinion

These financial statements are the responsibility of the Plan’s management. Our responsibility is to express an opinion on the Plan’s financial statements based on our audit. We are a public accounting firm registered with the Public Accounting Oversight Board (United States) (“PCAOB”) and are required to be independent with respect to the Plan in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.

We conducted our audit in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. The Plan is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audit we are required to obtain an understanding of internal control over financial reporting but not for the purpose of expressing an opinion on the effectiveness of the Plan’s internal control over financial reporting. Accordingly, we express no such opinion.

Our audit included performing procedures to assess the risk of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audit also included evaluating the accounting principles used and significant estimates made by the Plan’s management, as well as evaluating the overall presentation of the financial statements. We believe that our audit provides a reasonable basis for our opinion.

/s/ BDO USA, LLP

We served as the Plan’s auditor from 2015 to 2020.

Madison, Wisconsin
June 29, 2020

**EXACT SCIENCES CORPORATION 401(K) PLAN
STATEMENTS OF NET ASSETS AVAILABLE FOR BENEFITS
AS OF DECEMBER 31, 2020 AND 2019**

	December 31,	
	2020	2019
Assets		
Mutual funds	\$ 268,311,826	\$ 86,155,547
Common collective trusts	5,099,546	1,620,086
Exact Sciences Corporation common stock	74,874,135	46,896,822
Investments, at fair value	348,285,507	134,672,455
Employer matching contribution receivable	23,022,093	12,007,633
Participant loans receivable	1,959,982	600,379
Total assets	373,267,582	147,280,467
Liabilities	—	—
Net assets available for benefits, at fair value	\$ 373,267,582	\$ 147,280,467

See accompanying notes to the financial statements.

**EXACT SCIENCES CORPORATION 401(K) PLAN
STATEMENT OF CHANGES IN NET ASSETS AVAILABLE FOR BENEFITS
YEAR ENDED DECEMBER 31, 2020**

	2020
Additions	
Investment income	
Interest and dividend income	\$ 8,274,059
Net appreciation in fair value of investments	79,072,882
Total investment income	<u>87,346,941</u>
Interest from participant loans	<u>88,561</u>
Contributions	
Participant	36,403,145
Employer	23,023,324
Rollover	15,097,814
Total contributions	<u>74,524,283</u>
Total additions	161,959,785
Deductions	
Benefits paid directly to participants	18,694,359
Administrative expenses	200,703
Total deductions	<u>18,895,062</u>
Transfers into Plan (Note 1)	82,922,392
Net increase	225,987,115
Net assets available for benefits, beginning of year	147,280,467
Net assets available for benefits, end of year	<u>\$ 373,267,582</u>

See accompanying notes to the financial statements.

**EXACT SCIENCES CORPORATION 401(K) PLAN
NOTES TO FINANCIAL STATEMENTS**

1. Description of Plan

The following description of the Exact Sciences Corporation 401(k) Plan and its related trust (collectively, the “Plan”) is provided for general information purposes only. Participants should refer to the current Plan document for a complete description of the Plan’s provisions.

General

The Plan is a defined contribution plan, which was established by Exact Sciences Corporation (the “Company”) on January 1, 1998, and provides for elective contributions on the part of the participating employees and employer matching contributions in a discretionary amount, generally up to 6% of employees’ eligible compensation within limits established by the Internal Revenue Code of 1986 (“IRC”). The Plan extends coverage to each U.S. employee of the Company. Independent contractors are excluded from coverage. The Plan has designated the Company as the Plan Administrator, and the Company has delegated administrative responsibilities to the Exact Sciences Benefits Committee and investment responsibilities to the Exact Sciences 401(k) Investment Committee. The Plan Administrator is responsible for the operations of the Plan in accordance with prevailing government requirements. The Plan is subject to the provisions of the Employee Retirement Income Security Act of 1974, as amended (“ERISA”) and provisions of the IRC as it pertains to plans intended to qualify under IRC Section 401(a).

In September 2019, the Biomatrix, Inc. 401(k) Plan merged with an into the Plan. Assets totaling \$527,672 were transferred into the Plan in connection with such merger.

In November 2019, the Company completed the acquisition of Genomic Health, Inc. During 2019, employees of Genomic Health, Inc., were eligible to participate in the Genomic Health, Inc. 401(k) Plan (“Genomic Health Plan”), not the Plan. Genomic Health employees became eligible to participate in the Plan effective January 1, 2020. In April 2020, the Genomic Health Plan merged with and into the Plan. Assets totaling \$82,922,392 were transferred into the Plan in connection with such merger.

On March 27, 2020, President Trump signed into law the “Coronavirus Aid, Relief, and Economic Security (CARES) Act.” The CARES Act, among other things, includes several relief provisions available to tax-qualified retirement plans and their participants. Plan management has evaluated the relief provisions available to plan participants under the CARES Act and has implemented the following provisions:

- Special coronavirus distributions up to \$100,000,
- Extend the period for loan repayments, if applicable, up to one year, and
- Suspended required minimum distributions for 2020.

Plan Amendments and Addendums

Effective January 1, 2020, the participating employers addendum was updated to add Genomic Health, Inc., as a participating subsidiary. Effective March 24, 2020, the plan mergers addendum was amended to document the merger of the Genomic Health, Inc. 401(k) Plan into the Plan, and the adoption agreement was amended to provide for immediate vesting for prior employer contributions made to the Genomic Health, Inc. 401(k) Plan. Effective January 21, 2020, the adoption agreement was amended to set the maximum deferral percentage to 75%. Effective September 8, 2020, the adoption agreement was amended to permit reasonable costs and expenses of administering the plan to be paid from the forfeiture and suspense accounts and from the trust fund and to describe how amounts are credited to participant accounts. The September 8, 2020, amendment also allowed participants who have an outstanding loan balance when they terminate employment to continue to pay the loan in accordance with the provisions of the loan.

**EXACT SCIENCES CORPORATION 401(K) PLAN
NOTES TO FINANCIAL STATEMENTS**

Contributions

Plan participants are permitted to make contributions, either pre-tax or Roth contributions, in specified percentages of their annual eligible compensation, subject to certain additional limitations under the IRC. Participants can suspend their contributions at any time and still remain in the Plan. Participants can resume contributions and can change their elected contribution rate, on a prospective basis, at any time. The Plan permits an eligible participant to make pre-tax contributions in excess of the IRC 402(g) limit. These contributions are known as “catch-up contributions.” A participant who attains age 50 during a Plan year is permitted to make catch-up contributions to the Plan, subject to the legal limit on these contributions. The legal limit on catch-up contributions was \$6,500 during 2020.

Effective March 1, 2018, the Plan activated automatic enrollment. Under the automatic enrollment provision, an initial pre-tax deferral contribution of 6% is made for (a) newly eligible employees 30 days after such employee’s date of hire, but no sooner than such employee’s entry date, (b) active participants (who were not suspended from making deferral contributions) beginning on April 1, 2018, if they were without a deferral election on file, and (c) each eligible employee having a reemployment commencement date on the later of 30 days from the date of rehire or their entry date. Employees are free to opt out of automatic enrollment.

The Company may make matching contributions in a discretionary amount determined each year. For the years ended December 31, 2020, and December 31, 2019, matching contributions were made in whole shares of the Company’s common stock equal to 100% of an eligible participant’s pre-tax elective contributions and Roth elective deferrals up to a maximum of 6% of the participant’s annual eligible compensation, rounded to the nearest whole share, and within limits established by ERISA and the IRC. Matching contributions are made once a year following the Plan year to the participant’s account, provided that, the participant is employed by the Company as of the last day of the Plan year or meets the death, disability, or retirement exceptions to continuing eligibility requirements.

Participants’ Accounts

Each participant’s account is credited with the elective contributions made by that participant and the employer matching contributions made by the Company with respect to the participant. The participating employees direct the investment of their elective contributions credited to their account into one or more of the investment choices which have been made available to them. Matching contributions are made in the Company’s common stock but the participants have the option to redirect the investment of the matching contributions credited to their accounts into one or more of the investment choices which have been made available to them. Voting rights are retained by the participants holding the Company’s common stock. Each participant’s account will be credited with its share of the net investment earnings of the funds in which that account is invested. The employees individually enroll in the investment funds of their choice and the investment results directly affect their investment balances. The benefit to which a participant is entitled is the amount that can be provided from the participant’s vested account. The Plan also accepts rollover contributions (i.e., amounts which can be rolled over into a tax qualified plan from another employer’s tax qualified plan).

Vesting

The portion of a participant’s account attributed to elective contributions, qualified non-elective contributions and rollover contributions is fully vested at all times. Vesting of other amounts (e.g., fully vested rights to the portion of a participant’s account arising from employer matching contributions) occurs after the participant’s period of service reaches one year. A period of service is measured from an employee’s employment or reemployment commencement date and ends on an employee’s termination date. Notwithstanding the number of years in an employee’s period of service, a participant is considered fully vested in the event of retirement, death or disability while employed.

**EXACT SCIENCES CORPORATION 401(K) PLAN
NOTES TO FINANCIAL STATEMENTS**

Forfeitures

Forfeitures of terminated participants' non-vested accounts may be used to pay permissible Plan expenses in accordance with the rules under ERISA and any excess may be applied as a reduction to employer matching contributions, discretionary non-elective contributions or profit sharing contributions. Forfeitures occur in any Plan year in which a terminated participant receives the vested portion of his or her account and consequently forfeits the non-vested balance or in which a terminated participant who does not elect to receive distribution incurs a five-year break in service. If a terminated participant resumes employment with the employer within five years subsequent to the termination date, forfeited amounts may be restored to his or her account. For the year ended December 31, 2020, \$93,165 was forfeited from participants' non-vested accounts. As of December 31, 2020, and 2019, \$54,928 and \$55,438 remained in the forfeiture account, respectively.

Payment of Benefits

Benefits are generally payable following a participant's termination of employment, death or disability. Benefits are generally payable in a lump sum but may also be paid in installments or through partial withdrawals. Upon demonstration of substantial hardship, and in accordance with specific rules set forth by the Internal Revenue Service ("IRS") concerning hardship withdrawals, a participant may withdraw elective deferrals, which have not previously been withdrawn, subject to certain limitations.

Administrative Expenses

All of the Plan's administrative expenses, primarily comprised of the costs related to printing and mailing communications to participants, and audit and legal fees, are paid by the Company, with the exception of administrative expenses for terminated employees. All investment related expenses are paid by the participants.

2. Summary of Significant Accounting Policies

Basis of Accounting

The financial statements of the Plan have been prepared on the accrual basis of accounting.

Use of Estimates

The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, and changes therein, and disclosures of contingent assets and liabilities. Actual results could differ from those estimates.

Risks and Uncertainties

The Plan invests in various investment securities including mutual funds, common collective trusts and Company common stock. Investment securities are exposed to various risks, such as interest rate, market, equity price and credit risks. Due to the level of risk associated with certain investment securities, it is at least reasonably possible that changes in the values of investment securities will occur in the near term and such changes could materially affect participants' account balances and the amounts reported in the statements of net assets available for benefits.

**EXACT SCIENCES CORPORATION 401(K) PLAN
NOTES TO FINANCIAL STATEMENTS**

COVID-19 and CARES Act

On January 30, 2020, the World Health Organization ("WHO") announced a global health emergency because of a new strain of coronavirus originating in Wuhan, China (the "COVID-19 outbreak") and the risks to the international community as the virus spreads globally beyond its point of origin. In March 2020, the WHO classified the COVID-19 outbreak as a pandemic, based on the rapid increase in exposure globally.

The full impact of the COVID-19 outbreak continues to evolve as of the date of this report. This pandemic has adversely affected global economic activity and greatly contributed to significant deterioration and instability in financial markets. Because the values of the Plan's individual investments have and will fluctuate in response to changing market conditions, the amount of losses that will be recognized in subsequent periods, if any, and related impact on the Plan's liquidity cannot be determined at this time.

Investment Valuation and Income Recognition

All investments are carried at fair value or an approximation of fair value. Dividends are recorded on the ex-dividend date and interest is accrued as earned. Purchases and sales of securities are recorded on a trade-date basis. Net appreciation (depreciation) includes the Plan's gains and losses on investments bought and sold as well as held during the year.

Participant Loans Receivable

The Plan allows participants to borrow up to the lesser of half of his or her vested account balance or \$50,000. Loans are repaid via after-tax payroll deductions over a period of 60 months. If the loan is for the purchase of a principal residence, the participant may extend to a period of 120 months. Interest rates are set at the date of the loan at the prime rate plus 2% on the first day of the month in which the loan is taken. Interest rates range from 3.25% to 7.5% for loans outstanding at December 31, 2020. Upon termination, the entire outstanding loan balance is due immediately. Any default in repayment will result in a taxable distribution to the participant. Participant loans receivable are measured at their unpaid principal balance plus any accrued but unpaid interest.

Fair Value Measurements

The following provides a description of the three levels of input that may be used to measure fair value under Accounting Standards Codification 820, the types of Plan investments that fall under each category, and the valuation methodologies used to measure these investments at fair value.

Level 1 — Quoted prices available in active markets for identical assets or liabilities;

Level 2 — Inputs other than Level 1 inputs that are directly or indirectly observable;

Level 3 — Unobservable inputs in which little or no market data exists

**EXACT SCIENCES CORPORATION 401(K) PLAN
NOTES TO FINANCIAL STATEMENTS**

The following table presents the financial assets the Plan measures at fair value on a recurring basis, based upon fair value hierarchy as of December 31, 2020, and 2019:

Description	Fair Value Measurement at December 31, 2020			
	Quoted Prices in Active Markets for Identical Assets (Level 1)	Significant Other Observable Inputs (Level 2)	Significant Unobservable Inputs (Level 3)	Fair Value at December 31, 2020
Mutual funds	\$ 268,311,826	\$ —	\$ —	\$ 268,311,826
Exact Sciences Corporation common stock	74,874,135	—	—	74,874,135
Total investments at fair value	<u>\$ 343,185,961</u>	<u>\$ —</u>	<u>\$ —</u>	<u>\$ 343,185,961</u>
Investments at net asset value*				5,099,546
Total investments				<u>\$ 348,285,507</u>

Description	Fair Value Measurement at December 31, 2019			
	Quoted Prices in Active Markets for Identical Assets (Level 1)	Significant Other Observable Inputs (Level 2)	Significant Unobservable Inputs (Level 3)	Fair Value at December 31, 2019
Mutual funds	\$ 86,155,547	\$ —	\$ —	\$ 86,155,547
Exact Sciences Corporation common stock	46,896,822	—	—	46,896,822
Total investments at fair value	<u>\$ 133,052,369</u>	<u>\$ —</u>	<u>\$ —</u>	<u>\$ 133,052,369</u>
Investments at net asset value*				1,620,086
Total investments				<u>\$ 134,672,455</u>

* The investment in common collective trusts are measured at fair value using the net asset value per share (or its equivalent) practical expedient and has not been categorized in the fair value hierarchy. The fair value amounts presented in this table are intended to permit reconciliation of the fair value hierarchy to the amounts presented in the statements of net assets available for benefits.

The following are descriptions of the composition and valuation of Plan assets measured at fair value:

Mutual Funds — Mutual funds consist of publicly traded funds of registered investment companies. The fair value of these investments is determined by reference to the fair value of the underlying securities of the mutual funds. The net asset value of the mutual fund's shares is quoted on the exchange where the fund is traded in an active market.

**EXACT SCIENCES CORPORATION 401(K) PLAN
NOTES TO FINANCIAL STATEMENTS**

Common Collective Trusts - Valued at the net asset value (NAV) of the units held by the Plan which are based on the quoted market prices of the underlying securities of the funds. The NAV, as provided by the trustee, is used as a practical expedient to estimating fair value. The NAV is based on the value of the underlying investment assets owned by the fund, minus its liabilities, and then divided by the number of shares outstanding. The Common Collective Trusts have (1) no unfunded commitments, (2) a daily redemption frequency, and (3) a redemption notice period of up to 12 months as of December 31, 2020 and 2019.

Exact Sciences Corporation Common Stock - The Exact Sciences Corporation common stock fund contains the Plan's investment in the Company's common stock and is based on the unadjusted quoted market price. As a result, the fair value of the stock is classified in its entirety as Level 1 within the valuation hierarchy.

A financial instrument's level within the fair value hierarchy is based on the lowest level of any input that is significant to the fair value measurement. The methods described above may produce a fair value calculation that may not be indicative of net realizable value or reflective of future fair values. Furthermore, while management believes its valuation methods are appropriate and consistent with other market participants, the use of different methodologies or assumptions to determine the fair value of certain financial instruments could result in a different fair value measurement at the reporting date.

Benefits

Benefits are recorded when paid.

Party-in-Interest Transactions

Some of the registered investment companies the Plan invests in are managed by affiliates of the Fidelity Management Trust Company. Fidelity Management Trust Company acts as trustee for investments of the Plan. The Plan also invests in shares of the Company's common stock. Therefore, Plan transactions involving these investment securities qualify as party-in-interest transactions. All of these transactions are exempt from the prohibited transaction rules of ERISA.

The Plan issues loans to participants, which are secured by the balances in the participants' accounts. These transactions qualify as party-in-interest transactions.

Concentration of Investments

Included in investments at December 31, 2020, and 2019 are 565,117 and 507,087 shares of the Company's common stock amounting to \$74,874,135 and \$46,896,822, respectively. This investment represents 21% and 35% of total investments at December 31, 2020, and 2019, respectively. A significant decline in the market value of the Company's common stock would significantly affect the net assets available for benefits. During the year ended December 31, 2020, purchases of Exact Sciences common stock by the Plan totaled \$12,644,651 million and sales of Exact Sciences common stock by the Plan totaled \$9,086,623 million.

**EXACT SCIENCES CORPORATION 401(K) PLAN
NOTES TO FINANCIAL STATEMENTS**

3. Income Tax Status

The Plan has adopted the Fidelity Volume Submitter Profit Sharing Plan with CODA. The Fidelity Volume Submitter Profit Sharing Plan received a favorable opinion letter from the Internal Revenue Service (“IRS”) on March 31, 2014, stating that the Fidelity Volume Submitter Profit Sharing Plan is qualified, under the Internal Revenue Code (“IRC”) and, therefore, the related trust is exempt from taxation. The Plan has been amended since the aforementioned date of the opinion letter. However, the Plan administrator believes that the Plan is currently designed, and being operated in, compliance with the applicable requirements of the IRC. The plan administrator is taking action consistent with the Employee Plans Compliance Resolution System (EPCRS) correction methods to correct certain operational errors. Therefore, they believe that the Plan was qualified, and the related trust was tax-exempt as of the financial statement date and no provision for income taxes has been included in the Plan's financial statements.

Accounting principles generally accepted in the United States of America require plan management to evaluate uncertain tax positions. The financial statement effects of a tax position are recognized when the position is more likely than not, based on the technical merits, to be sustained upon examination by the IRS. The Plan has recognized no interest or penalties related to uncertain tax positions. The Plan is subject to routine audits by taxing jurisdictions. There are currently no audits for any tax periods in progress.

4. Trustee and Custodian

The funds of the Plan are maintained under a Trust with the Fidelity Management Trust Company as Trustee. The duties and authority of the Trustee are defined in the related Trust Agreement.

The Custodian of the Plan for the year ended December 31, 2020, and 2019 was Fidelity Management Trust Company. The duties of the Custodian include administration of the trust fund (including income) at the direction of the Trustee, the payment of benefits and loans to plan participants and the payment of expenses incurred by the Plan in accordance with instructions from the Plan Administrator and Trustee (with the option given to participants to individually direct the investment of their interest in the Plan). The Custodian is also responsible for the maintenance of the individual participant records and required to render statements to the participants as to their interest in the Plan.

5. Termination

Although it has not expressed any intent to do so, the Company has the right, in accordance with the Plan document, to terminate its participation in the Plan, subject to the provisions of ERISA and the IRC. If the Plan is fully or partially terminated, all amounts credited to the affected participants' accounts will become fully vested. Upon termination, the Plan Administrator will take steps necessary to have the assets of the Plan distributed among the affected participants.

6. Subsequent Events

The Company has evaluated subsequent events through June 29, 2021, the date the financial statements were issued.

**EXACT SCIENCES CORPORATION 401(K) PLAN
NOTES TO FINANCIAL STATEMENTS**

Plan Amendments and Addendums

Effective January 1, 2021, the participating employers addendum was updated to add Paradigm Diagnostics as a participating subsidiary. Also effective January 1, 2021, the adoption agreement was amended to exclude interns hired on or after January 1, 2021, from being eligible to participate in the Plan and also to remove the early retirement and disability exceptions for purposes of the employer discretionary match. Effective May 3, 2021, the plan mergers addendum was amended to document the merger of the Paradigm Diagnostics 401(k) Plan into the Plan and to carry over the definition of "disability" for participants of the Paradigm Diagnostics 401(k) Plan. The May 3, 2021, amendment also carried over the vesting schedule from the Paradigm Diagnostics 401(k) Plan for terminated participants. Effective February 4, 2021, the adoption agreement was amended to set the bonus deferral to zero. Effective April 14, 2021, the adoption agreement was amended to include prior service at Ashion Analytics, LLC, and Translational Genomics Research Institute for vesting purposes and to add a definition of disability to align with the provision in place for Ashion Analytics, LLC, employees prior to the acquisition of Ashion Analytics, LLC. Effective May 3, 2021, the Paradigm Diagnostics 401(k) plan was merged with and into the Plan. As a result, assets totaling approximately \$3.4 million were transferred into the Plan.

Exact Sciences Corporation 401(k) Plan
Schedule H, Part IV, Line 4a - Schedule of Delinquent Participant Contributions
For the Year Ended December 31, 2020

EIN 02-0478229
 Plan # 001

Total That Constitute Nonexempt Prohibited Transactions

Plan Year	Participant Contributions and Loan Repayments Transferred Late to Plan	Contributions Not Corrected	Contributions Corrected Outside VFCP	Contributions Pending Correction in VFCP	Total Fully Corrected Under VFCP and PTE 2002-51
2020 (1)	\$ 405,866	\$ —	\$ 405,866	\$ —	\$ —

(1) Withheld deferral in May 2020, transferred on June 18, 2020.

Exact Sciences Corporation 401(k) Plan
Schedule H, Part IV, Line 4i - Schedule of Assets (Held at End of Year)
As of December 31, 2020

EIN 02-0478229
 Plan # 001

(a)	(b) Identity of Issue, Borrower, Lessor or Similar Party	(c) Description of Investment Including Maturity Date, Rate of Interest, Collateral, Par, or Maturity Value	(d) Cost	(e) Current Value
Mutual funds				
*	Fidelity Investments	Fid US Bond Idx	**	\$ 2,452,911
*	Fidelity Investments	Fid Mid Cap Idx	**	\$ 7,772,522
*	Fidelity Investments	Fid Real Estate Idx	**	\$ 1,565,816
*	Fidelity Investments	Fid Sm Cap Idx	**	\$ 6,195,910
*	Fidelity Investments	Fid Total Mkt Idx	**	\$ 21,989,712
*	Fidelity Investments	Fid Infl PR BD Idx	**	\$ 979,923
*	Fidelity Investments	Fid Total Bond K6	**	\$ 1,862,690
	Goldman Sachs Asset Management	GS Emerg Mkts EQ R6	**	\$ 3,222,714
	The Hartford	Hartford Midcap R6	**	\$ 5,255,550
	T. Rowe Price	TRP Retire I BAL I	**	\$ 126,385
	T. Rowe Price	TRP Retire I 2005 I	**	\$ 263,368
	T. Rowe Price	TRP Retire I 2010 I	**	\$ 433,117
	T. Rowe Price	TRP Retire I 2015 I	**	\$ 758,986
	T. Rowe Price	TRP Retire I 2020 I	**	\$ 6,620,467
	T. Rowe Price	TRP Retire I 2025 I	**	\$ 17,171,149
	T. Rowe Price	TRP Retire I 2030 I	**	\$ 30,221,806
	T. Rowe Price	TRP Retire I 2035 I	**	\$ 31,373,781
	T. Rowe Price	TRP Retire I 2040 I	**	\$ 28,393,746
	T. Rowe Price	TRP Retire I 2045 I	**	\$ 24,814,263
	T. Rowe Price	TRP Retire I 2050 I	**	\$ 22,093,078
	T. Rowe Price	TRP Retire I 2055 I	**	\$ 17,743,037
	T. Rowe Price	TRP Retire I 2060 I	**	\$ 7,902,850
	T. Rowe Price	TRP Overseas Stock I	**	\$ 2,578,375
	Federated Investors, Inc.	Fed IS High Yld BD R6	**	\$ 1,428,265
	BlackRock	Blkrk Global Alloc K	**	\$ 1,183,086
	Invesco	Invs Comstock R6	**	\$ 1,764,473
	Goldman Sachs Assets Management	GS Intl SM CP Ins R6	**	\$ 1,237,543

J.P. Morgan Asset Management	UM Behavioral Val R6	**	\$	959,912
Janus Henderson Triton Fund Class	J H Triton N	**	\$	4,938,094
Columbia Threadneedle Investments	Col Contran Core I3	**	\$	2,979,799
Columbia Threadneedle Investments	Col SEL Mid CP VL I3	**	\$	1,514,988
Franklin Templeton Investments	Franklin Growth R6	**	\$	9,216,437
American Funds U.S. Government Securities Fund	AF US Govt SEC R6	**	\$	1,297,073
Common collective trusts				
Putnam Investments	Putnam Stable Value Fund	**	\$	5,099,546
Company stock				
* Exact Sciences Corporation Common Stock	Company stock	**	\$	74,872,410
* Exact Sciences Corporation	Stock Purchase Account	**	\$	1,725
Investments, at fair value			\$	348,285,507
* Loans to participants	Interest rates ranging from 3.25% to 7.5% due between 2020 and 2039	—	\$	1,959,982
Total			\$	<u>350,245,489</u>

* *Party-in-interest to the Plan*

** *Participant directed investment, cost not required to be reported.*

See accompanying notes to the financial statements.

EXHIBIT INDEX

Exhibit Index No.	Description
23.1	Consent of PricewaterhouseCoopers, LLP
23.2	Consent of BDO USA, LLP

Consent of Independent Registered Public Accounting Firm

Exact Sciences Corporation 401(k) Plan
Madison, Wisconsin

We hereby consent to the incorporation by reference in the Registration Statement on Form S-8 (333-229780) of Exact Sciences Corporation of our report dated June 29, 2021, relating to the 2020 financial statements of Exact Sciences Corporation 401(k) Plan which appear in this Form 11-K for the year ended December 31, 2020.

/s/PricewaterhouseCoopers LLP

Chicago, Illinois
June 29, 2021

Consent of Independent Registered Public Accounting Firm

Exact Sciences Corporation 401(k) Plan
Madison, Wisconsin

We hereby consent to the incorporation by reference in the Registration Statement on Form S-8 (333-229780) of Exact Sciences Corporation of our report dated June 29, 2020, relating to the 2019 financial statements of Exact Sciences Corporation 401(k) Plan which appear in this Form 11-K for the year ended December 31, 2020.

/s/BDO USA, LLP

Madison, Wisconsin
June 29, 2021